Mayoly-Spindler SAS

Ipsen SA 's appetite for business development has not been sated and just over a month after agreeing to acquire Epizyme, Inc. , the French firm has furthered its cancer pipeline by getting access to

With valuations in freefall across the biotech sector, Ipsen SA has hit the M&A trail with its acquisition of US firm Epizyme, Inc. and its already-approved cancer drug Tazverik. The French group,

The perception of Ipsen SA as a conservative business has been turned on its head since David Loew took over as CEO in July 2020, with the French company becoming a flagbearer for mid-sized pharma b

Ipsen SA is set to bid adieu to its over-the-counter activities and concentrate on specialty pharma after announcing that it is in talks to sell its consumer healthcare business to fellow French grou